Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 23;122(38):e2426352122.
doi: 10.1073/pnas.2426352122. Epub 2025 Sep 16.

SLC39A8-mediated zinc dyshomeostasis potentiates kidney disease

Affiliations

SLC39A8-mediated zinc dyshomeostasis potentiates kidney disease

Zhaoxian Cai et al. Proc Natl Acad Sci U S A. .

Abstract

While numerous genetic risk loci are linked to kidney disease, a unifying therapeutic target for diverse renal pathologies remains elusive. Here, through large-cohort polymorphic locus screening, we identify the SLC39A8 A391T variant (rs13107325) as a shared modifier of multiple kidney diseases. Functional characterization using Slc39a8 A391T knock-in mice and kidney-specific Slc39a8 knockout mice reveals that loss of SLC39A8 function reduces renal zinc accumulation, thereby mitigating susceptibility to kidney injury and disease progression. Mechanistically, we demonstrate that perturbed zinc homeostasis drives renal damage, and limiting zinc levels-whether via impaired SLC39A8 activity or direct chelation-activates the zinc-AKT-FOXO1-G6PC axis to confer protection. Critically, zinc chelation with EDTA recapitulates this benefit, significantly preventing and ameliorating experimental acute and chronic kidney disease. These findings establish renal zinc homeostasis as a key therapeutic node, with SLC39A8 and zinc-modulating strategies representing promising avenues for treating a broad range of kidney diseases.

Keywords: SLC39A8; SLC39A8 A391T; kidney disease; rs13107325; zinc homeostasis.

PubMed Disclaimer

Conflict of interest statement

Competing interests statement:The authors declare no competing interest.

References

    1. Levey A. S., Coresh J., Chronic kidney disease. Lancet 379, 165–180 (2012). - PubMed
    1. Francis A., et al. , Chronic kidney disease and the global public health agenda: An international consensus. Nat. Rev. Nephrol. 20, 473–485 (2024). 10.1038/s41581-024-00820-6. - DOI - PubMed
    1. Ronco C., Bellomo R., Kellum J. A., Acute kidney injury. Lancet 394, 1949–1964 (2019). - PubMed
    1. Coca S. G., Singanamala S., Parikh C. R., Chronic kidney disease after acute kidney injury: A systematic review and meta-analysis. Kidney Int. 81, 442–448 (2012). - PMC - PubMed
    1. Kalantar-Zadeh K., et al. , Patient-centred approaches for the management of unpleasant symptoms in kidney disease. Nat. Rev. Nephrol. 18, 185–198 (2022). - PubMed

LinkOut - more resources